Allogeneic stem cell transplantation from matched related and unrelated donors in thalassemia major patients using a reduced toxicity fludarabine-based regimen

Bone Marrow Transplantation

Volumn 40, Issue 10, 2007, Pages 957-964

  Resnick, I B ^a   Aker, M ^a   Tsirigotis, P ^a   Shapira, M Y ^a   Abdul Hai, A ^a   Bitan, M ^a   Gesundheit, B ^a   Amar, A ^a   Ackerstein, A ^a   Samuel, S ^a   Slavin, S ^a   Or, R ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALLOPURINOL; AMIKACIN; BUSULFAN; CEFAZOLIN; COTRIMOXAZOLE; CYCLOSPORIN A; DEFEROXAMINE; DEFIBROTIDE; DIURETIC AGENT; FLUDARABINE; G NEUPOGEN; GANCICLOVIR; GENTAMICIN; IMMUNOSUPPRESSIVE AGENT; MEROPENEM; METHYLPREDNISOLONE; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; VANCOMYCIN;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BACTEREMIA; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTINUOUS INFUSION; CYTOMEGALOVIRUS INFECTION; DISEASE FREE SURVIVAL; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; FLUID THERAPY; FOLLOW UP; GRAFT SURVIVAL; HEMORRHAGIC CYSTITIS; HUMAN; HUMAN CELL; INCIDENCE; LIVER VENOOCCLUSIVE DISEASE; LIVING DONOR; LOW DRUG DOSE; MALE; MUCOSA INFLAMMATION; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT SAFETY; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; SURVIVAL RATE; THALASSEMIA MAJOR;

ADOLESCENT; ADULT; ANTILYMPHOCYTE SERUM; BETA-THALASSEMIA; BUSULFAN; CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT REJECTION; GRAFT VS HOST DISEASE; HUMANS; MALE; MIDDLE AGED; STEM CELL TRANSPLANTATION; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE;

EID: 35748970732     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705826     Document Type: Article

References (27)

1. Weatherall DJ, Clegg JB. Thalassemia - a global public health problem. Nat Med 1996; 2: 847-849.
2. Olivieri NF, Brittenham GM. Iron chelating therapy and the treatment of thalassemia. Blood 1997; 89: 739-761.
3. Olivieri N, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A et al. Survival in medically treated patients with homozygous ß-thalassemia. N Engl J Med 1994; 331: 574-578.
4. Olivieri NF. The ß-thalassemia. N Engl J Med 1999; 334: 99-109.
5. Lawson SE, Roberts IAG, Amrolia P, Dokal I, Szydlo R, Darbyshire PJ. Bone marrow transplantation for ß-thalassemia major: The UK experience in two pediatric centers. Br J Haematol 2003; 120: 289-295.
6. Lucarelli G, Andreani M, Angelucci E. The cure of thalassemia by bone marrow transplantation. Blood Rev 2002; 16: 81-85.
7. Gaziev D, Galiberti M, Lucarelli G, Polchi P, Giardini C, Angelucci E et al. Bone marrow transplantation from alternative donors for thalassemia: HLA-phenotypically identical relative and HLA-nonidentical sibling or parent transplants. Bone Marrow Transpl 2000; 15: 815-821.
8. La Nasa G, Giardini C, Argiolu F Locatelli F, Arras M, De Stefano P et al. Unrelated donor bone marrow transplantation for thalassemia: the effect of extended haplotypes. Blood 2002; 99: 4350-4356.
9. Lucarelli G, Galimberti M, Giardini C, Polchi P, Angelucci E, Baronciani D et al. Bone marrow transplantation in thalassemia. The experience of Pesaro. Ann NY Acad Sci 1998; 850: 270-275.
10. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-763.
11. Glucksberg, H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft versus host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18: 295-304.
12. Pugatsch T, Oppenheim A, Slavin S. Improved single-step PCR assay for sex identification post allogeneic sex-mismatched BMT. Bone Marrow Transplant 1996; 17: 273-275.
13. Nakamura Y, Leppert M, O'Connell P, Wolff R, Holm T, Culver M et al. Variable number of tandem repeat (VNTR) markers for human gene mapping. Science 1987; 235: 1616-1622.
14. Preacher KJ, Briggs NE. An interactive calculation tool for Fisher's exact probability test for 2 × 2 tables [Computer software], 2003. Available from http://www.psych.ku.edu/preacher/.
15. Lucarelli G, Clift RA, Galiberti M, Polchi P, Angelucci E, Baronciani D et al. Marrow transplantation for patients with thalassemia: results in class 3 patients. Blood 1996; 87: 2082-2088.
16. Lucarelli G, Clift RA, Galimberti M, Angelucci E, Giardini C, Baronciani D et al. Bone marrow transplantation in adult thalassemic patients. Blood 1999; 93: 1164-4167.
17. Bearman SI. Veno-occlusive disease of the liver. Curr Opin Oncol 2000; 12: 103-109.
18. De Lima M, Couriel D, Thall PF, Wang X, Madden T, Jones R et al. Once-daily intravenous busulfan and fludarabine: Clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 2004; 104: 857-864.
19. Resnick IB, Shapira MY, Slavin S. Nonmyeloablative stem cell transplantation and cell therapy for malignant and non-malignant diseases. Transpl Immunol 2005; 14: 207-219.
20. Iannone R, Casella JF, Fuchs EJ, Chen AR, Jones RJ, Woolfrey A el al. Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and betathalassemia. Biol Blood Marrow Transplant 2003; 9: 519-528.
21. Horan JT, Liesveld JL, Fenton P, Blumberg N, Walters MC. Hematopoietic stem cell transplantation for multiply transfused patients with sickle cell disease and thalassemia after low-dose total body irradiation, fludarabine, and rabbit anti-thymocyte globulin. Bone Marrow Transplant 2005; 35: 171-177.
22. Haselberger MB, Schwinghammer TL. Efficacy of mesna for prevention of hemorrhagic cystitis after high-dose cyclophosphamide therapy. Ann Pharmacother 1995; 29: 918-921.
23. Travis LB, Curtis RE, Glimelius B, Holowaty EJ, Van Leeuwen FE, Lynch CF et al. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. J Natl Cancer Inst 1995; 87 524-530.
24. Andreani M, Nesci S, Lucarelli G, Tonucci P, Rapa S, Angelucci E et al. Long-term survival of ex-thalassemic patients with persistent mixed chimerism after bone marrow transplantation. Bone Marrow Transpl 2000; 25: 401-404.
25. Storb R, Blume KG, O'Donnell MR, Chauncey T, Forman SJ, Deeg HJ et al. Cyclophosphamide and antithymocyte globulin to condition patients with aplastic anemia for allogeneic marrow transplantations: The experience in four centers. Biol Blood Marrow Transplant 2001; 7: 39-4.
26. Bacigalupo A. Antilymphocyte/thymocyte globulin for graft versus host disease prophylaxis: Efficacy and side effects. Bone Marrow Transpl 2005; 35: 225-231.
27. Remberger M, Storer B, Ringden O, Anasetti C. Association between pretransplant thymoglobulin and reduced non-relapse mortality after marrow transplantation from unrelated donors. Bone Marrow Transpl 2002; 29: 391-397.